ReviewThe AAPS journal2006
CNS drug delivery: opioid peptides and the blood-brain barrier.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Blocking mu-opioid receptors inhibits social bonding in rituals.Biology letters · 2020Trial
- Emerging Perspectives on Prime Editor Delivery to the Brain.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Therapeutic potential of thymoquinone and its nanoformulations in neuropsychological disorders: a comprehensive review on molecular mechanisms in preclinical studies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Therapeutic Potential of Orally Administered Rubiscolin-6.International journal of molecular sciences · 2023Review
- Only empathy-related traits, not being mimicked or endorphin release, influence social closeness and prosocial behavior.Scientific reports · 2023Article
- The efficacy and neural mechanism of acupuncture therapy in the treatment of visceral hypersensitivity in irritable bowel syndrome.Frontiers in neuroscience · 2023Review
- Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.Biomolecules · 2022Review
- Article
- The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia.Neuropsychiatric disease and treatment · 2021Article
- The aetiology of social deficits within mental health disorders: The role of the immune system and endogenous opioids.Brain, behavior, & immunity - health · 2020Review
- Isolation and characterization of glycosylated neuropeptides.Methods in enzymology · 2019Article
- TyrACS chemical neuroscience · 2018Article
- Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides.Chemical science · 2016Article
- Cyclic Opioid Peptides.Current medicinal chemistry · 2016Review
- Effects of fentanyl on pain and motor behaviors following a collagenase-induced intracerebral hemorrhage in rats.Journal of pain research · 2016Article
- Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?Journal of medicinal chemistry · 2014Article
- Factor V activator from Daboia russelli russelli venom destabilizes β-amyloid aggregate, the hallmark of Alzheimer disease.The Journal of biological chemistry · 2013Article
- Modulation of the cannabinoid receptors by hemopressin peptides.Life sciences · 2013Review
- sCD44 internalization in human trabecular meshwork cells.Investigative ophthalmology & visual science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Peptides are key regulators in cellular and intercellular physiological responses and possess enormous promise for the treatment of pathological conditions. Opioid peptide activity within the central nervous system (CNS) is of particular interest for the treatment of pain owing to the elevated potency of peptides and the centrally mediated actions of pain processes. Despite this potential, peptides have seen limited use as clinically viable drugs for the treatment of pain. Reasons for the limited use are primarily based in the physiochemical and biochemical nature of peptides. Numerous approaches have been devised in an attempt to improve peptide drug delivery to the brain, with variable results. This review describes different approaches to peptide design/modification and provides examples of the value of these strategies to CNS delivery of peptide drugs. The various modes of modification of therapeutic peptides may be amalgamated, creating more efficacious "hybrid" peptides, with synergistic delivery to the CNS. The ongoing development of these strategies provides promise that peptide drugs may be useful for the treatment of pain and other neurologically-based disease states in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.